Scilex Stock price
Is Scilex a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,133 stocks worldwide.
Key metrics
Scilex Stock Analysis
Analyst Opinions
6 Analysts have issued a Scilex forecast:
Analyst Opinions
6 Analysts have issued a Scilex forecast:
Don't miss a Thing! We will send you all news about Scilex directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Scilex Stock News
Company Profile
Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Its products include ZTlido, a prescription lidocaine topical product approved by the FDA for the relief of neuropathic pain associated with PHN, which is a form of post-shingles nerve pain, and e GLOPERBA oral solutions, an FDA-approved prophylactic treatment for painful gout flares in adults. The company was founded on February 21, 2020 and is headquartered in Palo Alto, CA.
| Head office | United States |
| CEO | Dr. Ji |
| Employees | 34 |
| Founded | 2020 |
| Website | www.scilexholding.com |


